Posted by Michael Wonder on 15 Dec 2022
Amivantamab for the treatment of patients with EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of amivantamab in the NHS in England.
Amivantamab is not recommended for the treatment of adults with locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy whose tumours have epidermal growth factor receptor exon 20 insertion mutations.
